PreciseDx is dedicated to supporting personalized and precise treatments for breast cancer. The company develops AI-powered diagnostic solutions for cancer detection and treatment.

PreciseDx

PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis. Combining AI with our patented Morphology Feature Array® (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.

Merck Global Health Innovation Fund

Mount Sinai Health System

Agilent Technologies

IBM Ventures

We are incredibly excited to announce the completion of our Series B funding, securing over $20M.

For more details, be sure to read the full announcement on our website: https://lnkd.in/eJJh7cZF

#TissueIsTheIssue #HealthcareInnovation #BreastCancer

Clinical Lab Products recently featured an article on PreciseDx's study, published in the Taylor & Francis Group's Journal of Medical Economics. The study highlights how our AI-driven PreciseBreast™ platform significantly reduces healthcare costs and enhances patient care.

Learn how the power of our advanced AI in assessing the risk of breast cancer recurrence is transforming oncology diagnostics and creating better outcomes for patients: https://lnkd.in/eemKqiHa 

#BreastCancer #AI #HealthcareInnovation #OncologyDiagnostics #PatientCare #PreciseDx #TissueIsTheIssue

Exciting news! The economic impact study for our PreciseBreast™ (PDxBr) risk assessment has been published in the July issue of the Journal of Medical Economics.

This study assessed the cost impact of using PreciseBreast™, an AI-augmented histopathology platform that predicts the 6-year risk of recurrence in early-stage invasive breast cancer patients to aid in the treatment decision process.

💡 The findings are compelling: In a hypothetical cohort of 1 million female members, using PreciseBreast™ as part of a recurrence risk evaluation resulted in a remarkable cost saving of $4M in just the first year, compared to the current standard of care alone. Over 6-years, savings increased to $12.5M.

Learn more and gain valuable insights into AI in medicine: https://lnkd.in/eRD4UnVe

#tissueistheissue #HealthcareInnovation #BreastCancer #AIinMedicine #MedicalEconomics #PreciseDx

As artificial intelligence is providing greater utility in healthcare, is it time to align these causes rather than view them as opposing forces? 

Validated AI may significantly enhance healthcare by improving diagnostics, fostering widespread adoption of personalized medicine, as well as reshaping various other facets of patient care.
 
The American Medical Association terms this technology 'augmented intelligence' rather than ‘artificial intelligence,’ emphasizing its role in supporting, instead of replacing, human decision-making. 
 
At PreciseDx, we recognize the vital role of AI-based tools in working alongside the cancer care team. Termed ‘Quantitative AI™’, we offer an assistive technology that informs care team decision-making. By harnessing this validated and published AI platform, we aim to empower healthcare providers with advanced diagnostic capabilities and personalized treatment insights to improve patient outcomes and drive innovation in healthcare.
 
A recent report by the AMA explores the transformative potential of augmented intelligence in healthcare and provides practical guidance for physicians using AI-based tools. Explore the full report here: https://lnkd.in/dVewapnj 
 
#AugmentedIntelligence #PersonalizedMedicine #HealthcareInnovation #TissueIsTheIssue

HIT Consultant Media recently featured our collaboration with COTA and Baptist Health South Florida.

They detail PreciseBreast™'s potential advantages:
- Faster Results: PreciseDx delivers results in just 48 hours, accelerating the treatment planning process.
- Reduced Cost: At a significantly lower price point (80% reduction), the test could increase access to this vital information.
- Improved Accuracy: By leveraging AI, PreciseBreast™ may offer more precise risk assessment compared to traditional methods.

Check out the full article for more information: https://lnkd.in/e4EQndTN

Thank you, Fred Pennic!

#TissueIsTheIssue

Exciting update from #ASCO2024!

This weekend, our Co-Founder and Chief Medical Officer, Dr. Michael J. Donovan PhD, MD, presented at the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting. His poster session showcased the findings from our ongoing collaboration with the Laboratory for Pathology Dordrecht Albert Schweitzer Hospital in the Netherlands (NTH). 

Since its conception, this collaboration has made remarkable achievements in advancing invasive breast cancer diagnostic and treatment protocols. We are incredibly proud of Dr. Donovan and our team's dedication to pushing the boundaries of precision oncology diagnostics to ultimately improve patient outcomes globally.

For an in-depth look at the poster and to explore the detailed findings of this ongoing study, visit our website: https://lnkd.in/eAisDbr2

#TissueIsTheIssue #HealthcareInnovation #PreciseDx

We're excited to continue this important work together to improve accuracy and precision in diagnostic treatment decisions!

One in eight women in the U.S. will be diagnosed with breast cancer in their lifetime. To that end, it's crucial that clinical care teams accurately assess the risk of breast cancer recurrence in an effort to characterize the diagnosis properly and streamline treatment decisions.

Today, we are announcing a new collaboration with COTA and Baptist Health South Florida to assess and validate the performance of our PreciseBreast™ test to combat this pressing issue. The test seeks to validate the efficacy of the AI-enabled test and its ability to predict the likelihood of invasive breast cancer (IBC) recurrence.

Head to our website to learn more about the exciting new collaboration: https://lnkd.in/ehArUHsH

#TissueIsTheIssue #OncologyDiagnostics #PrecisionMedicine #Collaboration #Innovation

We are excited to announce our participation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Our Co-Founder and Chief Medical Officer, Michael J. Donovan PhD, MD, will be presenting a poster session on June 1, showcasing the findings from our ongoing collaboration with the Laboratory for Pathology Dordrecht Albert Schweitzer Hospital in the Netherlands (NTH).

The ASCO Annual Meeting provides an invaluable platform for us to engage with fellow oncology professionals on a global scale. We look forward to discussing our study’s results, exchanging ideas, and exploring how we can drive the field of oncology forward together.

For more information on the study and presentation details, please refer to the official announcement on our site: https://lnkd.in/ehArUHsH

#ASCO2024 #PreciseDx #TissueIsTheIssue

The Breast Cancer Research Foundation recently published a blog post that summarized ongoing research on the application of AI and predictive analytics in breast cancer. This research will help better understand the role of AI in transforming breast cancer care and facilitate a new era of precision diagnosis and treatment.

Here's a streamlined snapshot of some of their key insights:
- Personalized treatment plans are tailored for patients, optimizing outcomes.
- Predictive analytics utilize vast data to anticipate disease progression and treatment responses.
- Precision medicine advancements align patients with targeted therapies for enhanced efficacy.

It’s exciting to see the growing role of AI in healthcare, especially in cancer detection, and the increasing shift towards precision medicine. At PreciseDx, we are working with various investigators and collaborations to deliver AI-powered insights to the medical community for improved decision-making and patient care.

Read more: https://lnkd.in/ehhBtKsQ

#BCRF #PreciseDx #BreastCancerResearch #TissueIsTheIssue

PREC

AI:PRECISEDX

PreciseDx

locale

market

industry

website

linkedin

founding date

investor of

Metrics